Since KRAS mutations have emerged as frequent drivers of acquired resistance to anti-EGFR antibodies in CRC [28,29], their identification is crucial for diagnosis, monitoring, and treatment plan definition. The gene discussed is KRAS; the disease is colorectal carcinoma.